Rothblatt, United Therapeutics CEO, sells $3.4m in UTHR stock

Martine Rothblatt, Chairperson & CEO of United Therapeutics Corp (NASDAQ:UTHR), sold a total of $3.4 million in common stock on September 23 and 24. The sales were executed in multiple transactions with prices ranging from $416.51 to $435.84.

According to a Form 4 filing with the Securities and Exchange Commission, Rothblatt sold 2,000 shares on September 23, with the price ranging from $416.51 to $417.51, and another 2,000 shares ranging from $419.3025 to $420.27. On September 24, Rothblatt sold 3,316 shares, with prices ranging from $433.715 to $433.89, and 684 shares ranging from $435.84 to $436.84. According to InvestingPro, the company maintains excellent financial health with strong returns, and analysts have recently revised earnings estimates upward.

On the same dates, Rothblatt exercised stock options to acquire 8,000 shares of United Therapeutics common stock at a price of $120.26, for a total value of $962,080.

The transactions were executed under a pre-arranged 10b5-1 trading plan entered into on May 2, 2025. Following these transactions, Rothblatt directly owns 130 shares of United Therapeutics. Rothblatt also indirectly owns 324,518 shares by Trust, 258,117 shares by Trust, 45,596 shares by Trust, 15,962 shares by Trust, and 166 shares by Spouse.

In other recent news, United Therapeutics has reported positive results from its Phase 3 TETON-2 trial, which has attracted significant attention from analysts and investors. UBS has reiterated a Buy rating with a price target of $560, citing a potential $3-4 billion peak sales opportunity for the company’s Tyvaso drug in idiopathic pulmonary fibrosis (IPF). Meanwhile, Cantor Fitzgerald increased its price target to $525, describing the TETON-2 readout as a "best-case" scenario and raising the probability of success for Tyvaso to 90%. H.C. Wainwright also raised its price target to $500, estimating a 30% peak penetration for IPF by 2033 with a 75% probability of approval, leading to projected peak sales of $5.8 billion. UBS, in particular, noted that the positive trial results were unexpected by many investors and analysts, prompting them to increase their price target from $415 to $560. Jefferies raised its price target to $564, highlighting the drug’s achievement of a clinically meaningful improvement in forced vital capacity (FVC) compared to placebo. These developments underscore the increasing confidence in United Therapeutics’ potential for growth in the IPF market.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.